RxDoctor Payments Data

Ellis Levine, MD

Medical Oncology · Buffalo, NYNPI 1992703268

Payments from drug & device makers

What this record shows

This record is dominated by education: $121 of the $121 with a category attached, or 100.0%. Lilly USA, LLC accounts for 90.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.

$121in general payments, 2019–2025

Across 2 payments — averaging $60.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$109
  • Gilead$12
$205,442in research payments, 2019–2025

Across 147 payments — averaging $1397.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$97K
  • Genentech, Inc.$53K
  • E.r. Squibb & Sons, L.L.C.$52K
  • Merck$3K

What the payments were for

  • Education$121100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1$109
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121 in reported general payments places this provider in the 15th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024
$15,705
Medicare patients
94
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole13$282

Paid to pharmacies, not to this prescriber.

Other medical oncology in Buffalo

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →